Results of cervical cancer trial hailed as 'biggest breakthrough for decades'

14 October 2024

Findings from a CTC-led study into cervical cancer treatment have been published in the Lancet today, prompting further coverage for a trial which first caught the attention of the public last year.

Results for the INTERLACE trial have shown a course of treatment with existing drugs prior to chemoradiation led to a 35% reduction in the risk of death or return of cancer.

The results were first presented to the public at the ESMO conference last October. More information can be read in our article at the time.

The CTC media team interviewed the trial's CI, one of its patients, and one of the statisticians responsible for deciphering the results. The article was published as part of UCL's digital campaign for World Cancer Day this year.

External links

The Lancet | INTERLACE paper

The Guardian | New cervical cancer treatment regime 'cuts risk of dying from disease by 40%'

The Times | New treatment regimen cuts cervical cancer deaths by 40%

Sky News | Simple tweak to cervical cancer treatment cuts risk of death by 40%, say researchers

The Independent | Treatment cuts cervical cancer deaths by 40% in 'biggest breakthrough for decades'

Cancer Research UK | Cervical cancer treatment breakthrough cuts risk of death by 40%

More news articles

Research community marks International Clinical Trials Day

Today marks International Clinical Trials Day, a global initiative intended to highlight the advances being made in clinical research projec [...]

New blood test could help personalise treatment for advanced prostate cancer, CTC study finds

A CTC-led study has shown that measuring tumour DNA in the blood could help doctors identify earlier when treatment for advanced prostate ca [...]

EcoCAR project launched to introduce a sustainable approach to CAR T cell manufacturing

A new UK-wide research project is aiming to make the production of CAR T cell therapies faster, more efficient, and more environmentally sus [...]

Groundbreaking bowel cancer trial follow-up shows zero relapses

A CTC-led clinical trial has found that patients with a specific type of bowel cancer remained cancer-free nearly three years after receivin [...]

Cancer Research UK & UCL Cancer Trials Centre
University College London
149 Tottenham Court Road
London
W1T 7NF

View map

Email:
ctc.enquiries@ucl.ac.uk

Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)

Postal Address:
Cancer Research UK & UCL Cancer Trials Centre
University College London
20 Bedford Way
London WC1H 0AL

CTC staff

University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000